InnoCan Pharma(OTC) INNPF

Market Cap$7.29M

Since IPO (2020)-87%

5 Year-94%

1 Year-84%

1 Month-35%

$1.62

+0.00%

+0.00Today

InnoCan Pharma last closing stock price
Metric	Price	Date
Last close	USD 1.62	2026-08-19

InnoCan Pharma stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+13.29%	USD 1.43	2026-08-05
1 month	-34.68%	USD 2.48	2026-07-14
3 month	-46.53%	USD 3.03	2026-05-21
Year to date	-77.59%	USD 7.23	2025-12-30
1 year	-83.92%	USD 10.08	2025-08-15
3 year	-86.76%	USD 12.24	2023-08-18
5 year	-93.99%	USD 26.94	2021-08-18
Since inception	-87.07%	USD 12.53	2020-11-27

InnoCan Pharma Financials at a Glance

Market Cap

$7.29M

Revenue (TTM)

$25.19M

Net Income (TTM)

-$1.50M

EPS (TTM)

-$0.34

P/E Ratio

-4.81

Dividend

$0.00

Beta (Volatility)

1.76 (High)

Dividend

$0.00

Beta (Volatility)

1.76 (High)

Price

$1.62

Volume

100

Open

$1.62

Price

$1.62

Volume

100

Open

$1.62

Previous Close

$1.62

Daily Range

$1.62 - $1.62

52-Week Range

$0.13 - $14.26

Estimated Earnings Date

Nov 19, 2025

Dividend

$0.00

Beta (Volatility)

1.76 (High)

Price

$1.62

Volume

100

Open

$1.62

Previous Close

$1.62

Daily Range

$1.62 - $1.62

52-Week Range

$0.13 - $14.26

Estimated Earnings Date

Nov 19, 2025

INNPF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About InnoCan Pharma

INNOCAN PHARMA Corp is a pharmaceutical company focused on innovative drug delivery systems that integrate cannabidiol (CBD) with various pharmaceutical ingredients. The company operates in multiple international markets, including the United States and Europe, and is dedicated to research and development in CBD applications.

Products and Services

CBD-loaded exosomes for treating conditions like COVID-19
CBD-infused liposomes for enhanced drug delivery
Branded topical treatments, including CBD eye serum and recovery lotion

Growth Outlook

Recent quarterly revenue reached $6.38 million, indicating strong market demand
Research initiatives in CBD applications position the company for future growth
Expansion into international markets enhances revenue potential

Financial Highlights

Trailing twelve months (TTM) revenue of $25.5 million reflects a growing customer base
Current ratio of 5.24 indicates strong liquidity and financial health
Gross profit margin of 89.8% demonstrates effective cost management

INNOCAN PHARMA Corp is well-positioned in the pharmaceutical industry, particularly in the growing CBD market. The company's innovative approach to drug delivery systems and its commitment to research and development are key drivers of its potential for future growth. Recent financial performance highlights, including a significant quarterly revenue increase and a strong liquidity position, suggest a solid foundation for continued expansion. The focus on international markets further enhances the company's growth prospects, making it an intriguing option for investors interested in the pharmaceutical sector.

AI Generated • Aug 15, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

CEO

Iris Or Gabi Bincovich

Website

www.innocanpharma.com

Headquarters

Calgary, AB T2P 0N7, CA

INNPF Financials

Key Financial Metrics (TTM)

Gross Margin

89.81%

Operating Margin

-10.00%

Net Income Margin

-5.95%

Return on Equity

-31.76%

Return on Capital

-19.22%

Return on Assets

-13.80%

Earnings Yield

-20.79%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$7.29M

Shares Outstanding

4.50M

Volume

100

Avg. Volume

79.313

Financials (TTM)

Gross Profit

$22.62M

Operating Income

-$2.52M

EBITDA

-$683.22K

Operating Cash Flow

-$371.99K

Capital Expenditure

-$11.00K

Free Cash Flow

-$382.99K

Cash & ST Invst.

$6.70M

Total Debt

$1.42M

InnoCan Pharma Performance Analysis

InnoCan Pharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 2,559,000	1205.6%
2023	2023-12-31	USD 13,657,000	433.7%
2024	2024-12-31	USD 29,437,000	115.5%
2025	2025-12-31	USD 26,612,000	-9.6%

InnoCan Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-10.1%
Q3	2025-09-30	-3.7%
Q4	2025-12-31	-24.9%
Q1	2026-03-31	25.9%

InnoCan Pharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -0.98	-66.2%
2023	2023-12-31	USD -1.19	21.0%
2024	2024-12-31	USD -0.43	-64.2%
2025	2025-12-31	USD -0.25	-41.0%

InnoCan Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	N/A
Q3	2025-09-30	-230.8%
Q4	2025-12-31	202.3%
Q1	2026-03-31	-147.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$6.38M

-18.2%

Gross Profit

$5.81M

-18.4%

Gross Margin

91.11%

N/A

Market Cap

$7.29M

N/A

Market Cap/Employee

$662.55K

N/A

Employees

N/A

Net Income

-$958.54K

-64.7%

EBITDA

-$767.22K

-1767.9%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$6.70M

+5.2%

Total Debt

$1.42M

+9.3%

Accounts Receivable

$1.31M

+20.4%

Inventory

$2.19M

-26.0%

Long Term Debt

$969.18K

-25.6%

Short Term Debt

$453.49K

+6378.4%

Return on Assets

-13.80%

N/A

Return on Invested Capital

-28.28%

N/A

Free Cash Flow

-$498.99K

-237.5%

Operating Cash Flow

-$498.99K

-235.6%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

HITCHealthcare Integrated Technologies, Inc.

HITCHealthcare Integrated Technologies, Inc.$0.30+0.00%

RTGNRetinalGenix Technologies Inc.

RTGNRetinalGenix Technologies Inc.$4.00+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NVDANvidia

NVDANvidia$217.55-0.05%

PCGPG&E

PCGPG&E$16.60-0.08%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.45-0.03%

IRENIren

IRENIren$35.45-0.13%

INTCIntel

INTCIntel$89.47-0.03%

NUNu Holdings

NUNu Holdings$14.30-0.04%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$43.90-0.03%

Questions About INNPF

What is the current price of InnoCan Pharma?

InnoCan Pharma is trading at $1.62 per share.

What is the 52-week range for InnoCan Pharma?

Over the past 52 weeks, InnoCan Pharma has traded between $0.13 and $14.26.

How much debt does InnoCan Pharma have?

As of the most recent reporting period, InnoCan Pharma reported total debt of $1.42M.

How much cash does InnoCan Pharma have on hand?

InnoCan Pharma reported $6.67M in cash and cash equivalents in its most recent financial results.

What is InnoCan Pharma’s dividend yield?

InnoCan Pharma does not currently have a dividend yield.

InnoCan Pharma(OTC) INNPF

InnoCan Pharma Financials at a Glance

INNPF News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About InnoCan Pharma

INNPF Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

InnoCan Pharma Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About INNPF

What is the current price of InnoCan Pharma?

What is the 52-week range for InnoCan Pharma?

How much debt does InnoCan Pharma have?

How much cash does InnoCan Pharma have on hand?

What is InnoCan Pharma’s dividend yield?

Premium Investing Services